{
  "id": 1817,
  "text": "# 14.3 Development group comments Many of the trials in advanced and metastatic disease were undertaken prior to the adoption of concomitant chemotherapy into radiotherapy protocols and therefore the response rates to single agent cisplatin may differ according to whether patients received prior chemoradiotherapy or not.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: # 14.3 Development group comments Many of the trials in advanced and metastatic disease were undertaken prior to the adoption of concomitant chemotherapy into radiotherapy protocols and therefore the response rates to single agent cisplatin may differ according to whether patients received prior chemoradiotherapy or not.\n\n<question>: ",
  "ChatGPT_response_0": "有一些试验针对晚期和转移性疾病的患者进行了顺铂单药疗法的研究。这些试验中的患者有些接受过化疗放疗治疗方法，有些则没有接受过。在实施这些试验之前，许多试验是在采用同步化疗和放疗方案之前进行的，因此顺铂单药疗法的反应率可能会根据患者是否接受过化疗放疗治疗方法而有所不同。",
  "query": "在治疗晚期和转移性疾病时，是否对接受过化疗放疗治疗方法的患者以及未接受过的患者使用顺铂单药疗法进行了哪些试验？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗晚期和转移性疾病时，是否对接受过化疗放疗治疗方法的患者以及未接受过的患者使用顺铂单药疗法进行了哪些试验？\n\n<reference text>: # 14.3 Development group comments Many of the trials in advanced and metastatic disease were undertaken prior to the adoption of concomitant chemotherapy into radiotherapy protocols and therefore the response rates to single agent cisplatin may differ according to whether patients received prior chemoradiotherapy or not.\n\n<reply>: ",
  "response": "有一些试验针对晚期和转移性疾病的患者进行了顺铂单药疗法的研究。这些试验中的患者有些接受过化疗放疗治疗方法，有些则没有接受过。在实施这些试验之前，许多试验是在采用同步化疗和放疗方案之前进行的，因此顺铂单药疗法的反应率可能会根据患者是否接受过化疗放疗治疗方法而有所不同。"
}